Atazanavir Twice Daily

Bristol-Myers Squibb (BMS)

Status and phase: Completed; Phase 1

Conditions: Protease Inhibitor; HIV Infections

Treatments: Drug: Atazanavir Sulphate

Study type: Interventional

Funder types: Industry

Identifiers

NCT00357721

AI424-286

Details and patient eligibility

About

The purpose of this clinical research study is to assess the pharmacokinetics of atazanavir administered twice-daily relative to historical data from atazanavir/ritonavir 300/100 mg, given once daily.

Sex: All

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Healthy male and female subjects between the ages of 18 to 45 years old with a BMI of 18 to 30 kg/m2

Trial design

18 participants in 3 patient groups

A1

Active Comparator group

Treatment:

Drug: Atazanavir Sulphate

Drug: Atazanavir Sulphate

Drug: Atazanavir Sulphate

A2

Active Comparator group

Treatment:

Drug: Atazanavir Sulphate

Drug: Atazanavir Sulphate

Drug: Atazanavir Sulphate

A3

Active Comparator group

Treatment:

Drug: Atazanavir Sulphate

Drug: Atazanavir Sulphate

Drug: Atazanavir Sulphate